Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial
Retrieved on:
Thursday, October 7, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Infrared spectroscopy correlation table, Therapy, Ovarian cancer, Biotechnology, Intention, Drug development, Bachelor of Medicine, Bachelor of Surgery, Cancer, Webcast, Pneumonitis, SEC, Neutropenia, Center, AACR, Technology, Squamous cell carcinoma, Conference, COVID-19, Investor, Grade 3, U.S. Securities and Exchange Commission, Thromboxane A2, Toxic leukoencephalopathy, Neoplasm, Clinical trial, MRCP, DLT, NASDAQ, IHC, Bicycle, Tumor lysis syndrome, Phase, MMAE, Brentuximab vedotin, Review, Coagulopathy, Kidney, Private Securities Litigation Reform Act, Forward-looking statement, Risk, RECIST, Orange Riots, ADC, Security (finance), Neck, Breast, Patient, Anemia, Head, MT1-MMP, BTC, Pharmaceutical industry, Vaccine
We look forward to providing additional clinical data on BT5528 and BT8009 next year, and initiating our Phase I/II study for BT7480 later this year.
Key Points:
- We look forward to providing additional clinical data on BT5528 and BT8009 next year, and initiating our Phase I/II study for BT7480 later this year.
- BT5528, a BTC targeting EphA2, a target for which prior antibody-based approaches have been unsuccessful, has demonstrated preliminary anti-tumor activity.
- Doses of BT5528 administered to date have been tolerated in the ongoing Phase I portion of the Phase I/II trial.
- ET to review the BT5528 trial data being presented at the AACR-NCI-EORTC meeting and provide an update on preliminary findings from the BT8009 trial.